MA33302B1 - 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale - Google Patents

2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale

Info

Publication number
MA33302B1
MA33302B1 MA34394A MA34394A MA33302B1 MA 33302 B1 MA33302 B1 MA 33302B1 MA 34394 A MA34394 A MA 34394A MA 34394 A MA34394 A MA 34394A MA 33302 B1 MA33302 B1 MA 33302B1
Authority
MA
Morocco
Prior art keywords
excessive
treatment
cell proliferation
abnormal cell
diseases characterized
Prior art date
Application number
MA34394A
Other languages
Arabic (ar)
English (en)
Inventor
Ioannis Sapountzis
Heinz Stadtmueller
Daniel Kuhn
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA33302B1 publication Critical patent/MA33302B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRÉSENTE INVENTION PORTE SUR DES COMPOSÉS DE FORMULE GÉNÉRALE (1), DANS LAQUELLE A, B, R1 À R5, RX M, N ET P SONT TELS QUE DÉFINIS DANS LA REVENDICATION 1, QUI SONT APPROPRIÉS POUR LE TRAITEMENT DE MALADIES CARACTÉRISÉES PAR UNE PROLIFÉRATION CELLULAIRE EXCESSIVE OU ANORMALE. L'INVENTION PORTE ÉGALEMENT SUR DES PRÉPARATIONS PHARMACEUTIQUES QUI CONTIENNENT DE TELS COMPOSÉS ET SUR LEUR UTILISATION EN TANT QUE MÉDICAMENTS.
MA34394A 2009-05-29 2010-05-28 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale MA33302B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09161496 2009-05-29
EP10161628 2010-04-30
PCT/EP2010/057408 WO2010136559A1 (fr) 2009-05-29 2010-05-28 2, 4-diaminopyrimidines pour le traitement de maladies caractérisées par une prolifération cellulaire excessive ou anormale

Publications (1)

Publication Number Publication Date
MA33302B1 true MA33302B1 (fr) 2012-05-02

Family

ID=42289495

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34394A MA33302B1 (fr) 2009-05-29 2010-05-28 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale

Country Status (22)

Country Link
US (1) US8410126B2 (fr)
EP (1) EP2435411B1 (fr)
JP (1) JP5756799B2 (fr)
KR (1) KR20120135010A (fr)
CN (1) CN102448943A (fr)
AP (1) AP2011005978A0 (fr)
AR (1) AR076620A1 (fr)
AU (1) AU2010251943A1 (fr)
BR (1) BRPI1014994A2 (fr)
CA (1) CA2763700A1 (fr)
CL (1) CL2011003022A1 (fr)
CO (1) CO6470899A2 (fr)
EA (1) EA201101674A1 (fr)
EC (1) ECSP11011558A (fr)
IL (1) IL216084A0 (fr)
MA (1) MA33302B1 (fr)
MX (1) MX2011012643A (fr)
PE (1) PE20120370A1 (fr)
SG (1) SG176599A1 (fr)
TW (1) TW201107308A (fr)
UY (1) UY32673A (fr)
WO (1) WO2010136559A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008152195A (ru) * 2006-06-15 2010-07-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) 2-анилино-4-(гетероциклил)аминопиримидины, как ингибиторы протеинкиназы с-альфа
MX353308B (es) 2008-05-21 2018-01-08 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
US20130324532A1 (en) 2011-02-17 2013-12-05 Cancer Therapeutics Crc Pty Limited Fak inhibitors
US9174946B2 (en) 2011-02-17 2015-11-03 Cancer Therapeutics Crc Pty Ltd Selective FAK inhibitors
EP2704572B1 (fr) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Composés permettant d'inhiber la prolifération cellulaire dans les cancers induits par l'egfr
WO2013169401A1 (fr) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Composés pour inhiber la prolifération cellulaire dans les cancers induits par l'egfr
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
EP3475263B1 (fr) 2016-06-27 2022-12-28 Rigel Pharmaceuticals, Inc. Composés de 2,4-diaminopyrimidine et leur utilisation comme inhibiteurs de irak4
WO2019190259A1 (fr) * 2018-03-30 2019-10-03 한미약품 주식회사 Nouveau dérivé de sulfonamide ayant un effet inhibiteur sur la mutation du récepteur du facteur de croissance épidermique
PE20220597A1 (es) 2019-05-10 2022-04-22 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
US11518758B2 (en) 2019-05-10 2022-12-06 Deciphera Pharmaceuticals, Llc Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
EP3972414A4 (fr) * 2019-05-23 2023-07-26 Corteva Agriscience LLC Arylamidines fongicides
PE20221083A1 (es) 2019-06-17 2022-07-05 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso
WO2022208454A1 (fr) * 2021-04-02 2022-10-06 Bridge Biotherapeutics, Inc. Composés de n2-phénylpyrimidine-2,4-diamine et procédés de préparation et procédés d'utilisation correspondants
CN121358482A (zh) * 2023-06-09 2026-01-16 艾斯特里昂株式会社 用于预防或治疗脑肿瘤的药物组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0301932A3 (en) * 2000-05-22 2007-09-28 Leo Pharma As Benzophenones as inhibitors of il-1 beta and tnf-alpha, pharmaceutical compositions containing them and use of them for producing pharmaceutical compositions
WO2003030909A1 (fr) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer
ATE407678T1 (de) * 2001-10-17 2008-09-15 Boehringer Ingelheim Pharma Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
EP1518855B1 (fr) * 2002-06-28 2011-10-26 Astellas Pharma Inc. Derive de diaminopyrimidinecarboxamide
US7109337B2 (en) * 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
CA2529611C (fr) * 2002-12-20 2009-12-15 Pfizer Products Inc. Derives de pyrimidine destines au traitement de la croissance cellulaire anormale
BRPI0511138A (pt) * 2004-05-14 2007-11-27 Pfizer Prod Inc derivados de pirimidina para o tratamento de desenvolvimento celular anormal
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
PE20120006A1 (es) 2006-05-15 2012-02-02 Boehringer Ingelheim Int Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
JP5161233B2 (ja) * 2006-10-19 2013-03-13 ライジェル ファーマシューティカルズ， インコーポレイテッド 自己免疫疾患の処置のためのｊａｋキナーゼの阻害剤としての２，４−ピリミジンアミン誘導体
SG165655A1 (en) * 2008-04-16 2010-11-29 Portola Pharm Inc 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors
US8138339B2 (en) * 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases

Also Published As

Publication number Publication date
CN102448943A (zh) 2012-05-09
US20110130401A1 (en) 2011-06-02
UY32673A (es) 2010-12-31
BRPI1014994A2 (pt) 2016-05-03
SG176599A1 (en) 2012-01-30
CL2011003022A1 (es) 2012-07-13
EA201101674A1 (ru) 2012-06-29
KR20120135010A (ko) 2012-12-12
CO6470899A2 (es) 2012-06-29
ECSP11011558A (es) 2012-01-31
JP5756799B2 (ja) 2015-07-29
PE20120370A1 (es) 2012-05-09
TW201107308A (en) 2011-03-01
JP2012528121A (ja) 2012-11-12
EP2435411B1 (fr) 2014-10-29
WO2010136559A1 (fr) 2010-12-02
CA2763700A1 (fr) 2010-12-02
AR076620A1 (es) 2011-06-22
IL216084A0 (en) 2012-01-31
US8410126B2 (en) 2013-04-02
AU2010251943A1 (en) 2011-12-01
MX2011012643A (es) 2011-12-14
EP2435411A1 (fr) 2012-04-04
AP2011005978A0 (en) 2011-12-31

Similar Documents

Publication Publication Date Title
MA33302B1 (fr) 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale
TN2009000551A1 (fr) Nouveaux composes chimiques
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA32506B1 (fr) Nouveaux composes
MA34308B1 (fr) Triazolopyridines substituées
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA50240A (fr) Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation
MA33606B1 (fr) Dérivés de pyrimidine en tant qu'inhibiteurs de protéine tyrosine kinase 2
MA34474B1 (fr) Agonistes de gpr40
MA41562A1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MA31260B1 (fr) 3-imidazolyl-indoles pour le traitement de maladies proliferatives
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
TW200612926A (en) Compounds and compositions as ppar modulators
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
TN2015000547A1 (fr) Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA67288A1 (fr) Tubulysines et conjugués tubulysines-protéines
MA37990B1 (fr) Benzamides
MA33218B1 (fr) Applications therapeutiques de derives de quinazolinedione
MA31857B1 (fr) N-phenyl-pyrrolidinylmethylpyrrolidine-amides substitues et utilisation therapeutique de ceux -ci
MA37691B1 (fr) 5-amino[1,4]thiazines comme inhibiteurs de bace1
MA29723B1 (fr) Composes
MA37763A1 (fr) Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1